Scholars Central

Case reportPublished 2019

Durable Response to Immune Checkpoint Blockade Plus Albumin-Bound Paclitaxel in Two Osimertinib-Refractory Patients with EGFR-mutated Lung Adenocarcinoma

Authors: Bo Yang, Yaping Long, Zhibo Zhang, Yuheng Ma, Zhi Cui, Pengfei Cui, Xiaoyan Li, Yi Hu

Cancer Science & Therapy

Volume 11 · Issue 5 · Pages 175–177

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Osimertinib (AZD9291, Tagrisso) is an irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) compound. Limited effective therapeutic regimens are recommended for patients who progress with osimertinib. We retrospectively reviewed two patients with EGFR mutations who were resistant to osimertinib and received anti-programmed cell death-1 (anti-PD-1) agents combined with Abraxane with stage IV cancer. The two patients (one male and one female) were diagnosed with EGFR mutation-positive advanced lung adenocarcinoma and received first- or second-generation EGFR-TKIs. When these patients became resistant, both received osimertinib. Both patients had disease progression after osimertinib and received combination therapy of immune checkpoint blockade (nivolumab or pembrolizumab) and albumin-bound paclitaxel (Abraxane). These patients achieved partial remission (PR), and their progression-free survival (PFS) were respectively 8.0 months and 10.0 months. The combination of immunotherapy and Abraxane could be an effective option for the treatment of patients resistant to osimertinib.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Bo Yang”
  • BylineArticles whose byline prints “Yaping Long”
  • BylineArticles whose byline prints “Zhibo Zhang”
  • BylineArticles whose byline prints “Yuheng Ma”
  • BylineArticles whose byline prints “Zhi Cui”
  • BylineArticles whose byline prints “Pengfei Cui”
  • BylineArticles whose byline prints “Xiaoyan Li”
  • BylineArticles whose byline prints “Yi Hu”